OPKO Health to acquire 45% stake in Israeli hepatitis B vaccine maker

6 June 2012

Miami, USA-based OPKO Health (NYSE: OPK) has entered into a definitive agreement to acquire a 45% stake in an unnamed private Israeli company that produces a third-generation hepatitis B vaccine - Sci-B-Vac - in its state of the art biologics manufacturing facility in Rehovot. Financial terms of the transaction were not disclosed.

Sci-B-Vac is a recombinant mammalian cell produced next generation vaccine which has in multiple clinical studies demonstrated enhanced antibody response in a population of documented none and low-responders for which conventional hepatitis B vaccines do not elicit adequate antibody production. In addition, studies indicate that the vaccine induces rapid seroprotection and can be used for immunotherapy of chronic hepatitis B. Sci-B-Vac is currently marketed in Israel and has received marketing authorizations in several countries.

OPKO acquired its stake in the company from UK-based FDS Pharma, a manufacturer of active pharmaceutical ingredients for Russian and other markets. FDS acquired the company from Singapore-based biotech firm SciGen (ASX: SIE) in the first quarter of 2012.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical